1 / 63

Septic arthritis &post arthroplasty infections

Septic arthritis &post arthroplasty infections. Presenter R N MBUVA Moderator Mr MWANGI. scope. Septic arthritis Prosthetic infections. Part 1. Septic arthritis. Definition. Inflammation of a synovial membrane with purulent effusion into the joint capsule, often due to bacterial infection.

asabi
Download Presentation

Septic arthritis &post arthroplasty infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Septic arthritis &post arthroplasty infections Presenter R N MBUVA Moderator Mr MWANGI

  2. scope • Septic arthritis • Prosthetic infections

  3. Part 1

  4. Septic arthritis

  5. Definition • Inflammation of a synovial membrane with purulent effusion into the joint capsule, often due to bacterial infection

  6. Synonyms • Bacterial, suppurative, purulent or infectious arthritis, gonococcal or nongonococcal

  7. septic arthritis • 0.2%-0.7% of hospital admissions • Peak incidence in the first years of 1st decade and >50 years • Males>Females

  8. Risk Factors for Septic Arthritis • Previous arthritis • Trauma • Diabetes Mellitus • Immunosupression • Bacteremia • Sickle cell anemia • Prosthetic joint

  9. Infection Sources • Trauma: direct • Hematogenous: IV drug injection • Osteomyelitis adjacent to joint capsule • Soft tissue infections: cellulitis, abscess, bursitis, tenosynovitis

  10. Pathogenesis • Systemic bacteremia-invades synovial cartilage • Postulation-collagen receptors in staph aureus -lack of basement membrane in capillaries of synovium -synovial fibroblasts inhibit phagocytosis

  11. pathogenesis • Features of acute Infiltration • Lymphocytes 3/52 • Destruction of cartilage after ground substance degradation4-6/7 • Depletion of ground substance-activation of bacteria enzymes and T lymphocytes • Ground substance degradation-collagen exposed

  12. Up-to-Date 2004

  13. clinical presentation • Painful ROM, swelling, erythema, not bearing weight, recent illnesses • Children: • pseudoparalysis or disuse of limb, not septic • antalgic limp • Fevers not consistent • Have parent examine the child

  14. Labs • Leukocyte count not reliable early stages • 25% of children had elevated counts and 65% the diff was abnormal • ESR • Nonspecific test of inflammation • Affected by cell size, shape and protein content • i.e. sickle cell, anemia, steroids • Not reliable in neonates • Elevated in 48-72 hrs returns to baseline 2-4 weeks Mayo series, Morey et al: only 5 of 76 had ESR below 20mm/hr, elevated in 90% of patients w/ septic arthritis

  15. ESR • No change w/ antibiotic therapy • Continues to rise 3-5 days – after this may consider change in tx • Not good for early evaluation of tx

  16. CRP • Rises within 6 hrs and peaks 30-50hrs • Half life 47hrs • Makes this marker of greater value for early diagnosis and resolution of inflammation • CRP is elevated in trauma, in otitis media(22%bacterial 65% viral)

  17. Cultures • Blood cultures • yield organisms 30-50% of cases • Decreases w/ previous antibiotic therapy • Aspiration of joint fluid • Gram stain, leukocyte cell count, PMNs • Cell counts 80,000 – 100,000/ml likely septic arthritis • Frank and Nelson: 126 positive culture • Counts of 50,000/ml or less in 55%, 34% had <25,000/ml, only 44% had >=100,000/ml • Other inflammatory processes can give you >80,000/ml • Gram stain can give you a presumptive early diagnosis • 1/3 are positive

  18. Imaging • Plain x rays • Ultrasound • Used frequently in pediatrics assessing the hip for effusion/dislocations • Cannot differentiate between TSH and septic arthritis by positive effusion alone • If extracapsular effusion may distinguish between osteomyelitis around hip/pelvis • CT,MRI&Bone scans not necessary • Bone scan – Tc99-good osteoblastic activity indium111 and gallium citrate more sensitive and specific for infection i • CT scans-good anat,distinguishes soft tissue and bone infection • MRI sensitivity 97% and specificity 92%

  19. Kocher et al. 1999 • Hx of fever • Nonweightbearing • ESR >40mm/hr • WBC >12,000/mm3

  20. Kochers criteria • The likelihood of septic arthritis was • 0.2% if no criteria were present, • 3% if one • 40% if two • 93% if three • 99% if four • Unfortunately not reproducible • Caird et al-crp&esr –more likely • Luhmann-visit another facility more likely

  21. Management • Nade • Principles-1joint adequately drained 2ABX given to diminish effects of sepsis 3joint rested in a stable position

  22. Indications for Surgery • Aspiration vs. debridement • Joint does not respond to serial aspirations • No improvement in 48hrs of tx • Frank pus is aspirated • Loculations noted on MRI or U/S • Documented Hip and SI septic arthritis should be debrided surgically • No change in morbidity between arthroscopic vs. arthrotomy of knee

  23. Abx Treatment • IV abx 4-7 days • Check CRP,WBC every 2 days • Once labs normalize and clinically improving consider discharge • Continue tx 2-3 weeks with oral or IV abx (PICC line) • No true standardization of tx • Get ID involved

  24. Rehabilitation • Splinting for 48 hrs • Salter 1981 • Rabbit knees septic S. aureus • Had arthrotomy and abx tx • Casting vs. ROM w/ CPM vs. cage activity • CPM fared sig. better on pathology of cartilage w/ decreased ground substance • WBAT once rom and pain subsided

  25. Prognosis and complications • Poor prognosis factors • Immunodeficiency, RA, prematurity, osteomyelitis, hip, prosthetic infections, + blood cultures, symptoms >1 week, >4 joints, + cultures after aspiration after 7 days of abx tx • Complications: • Mortality 8%-15% in three series • arthritis stiffness, dislocation, subluxation, AVN, local growth distrubance, osteomyelitis, postinfection synovitis • Favorable outcome in 50%-80% of cases

  26. Lyme Arthritis • Caused by infection with the spirochete Borrelia Burgdorferi • Early stage disease • Localized - Erythema chronicum migrans, fever, arthralgia and myalgia, sore throat, • Disseminated- disseminated skin lesions, facial palsy, meningitis, radiculoneuropathy, and rarely heart block • Early disease may remit spontaneously • 50% of untreated cases develop late features • Late • Arthritis is a manifestation of late disease-months or years after exposure • Intermittent migratory asymmetric mono- or oligo-arthritis • 10% develop chronic large joint inflammatory arthritis

  27. Lyme Arthritis • Treatment • Early localized • Doxy 100 mg po BID or Amox 500 TID (kids) for 2-4 weeks • Early disseminated or late disease • Oral or parenteral abx depending on the severity of the disease • Neuro or cardiac disease usually treated with IV ceftriaxone 2 g daily for 3-4 weeks. • Lyme arthritis may be treated with oral abx for 4 weeks.

  28. Disseminated gonococcal infection • Occurs in 1-3% on patients infected with GC • Most patients have arthritis or arthralgia as a principal manifestation • Common cause of acute non-traumatic mono- or oligo-arthritis in the healthy host

  29. Gonococcal arthritisHost factors • Women > men • Recent menstruation • Pregnancy or immediate postpartum state • Complement deficiency (C5-C9) • SLE

  30. Gonococcal arthritis • Consider screening/treating for chlamydia • HIV testing • Syphillis testing • Screen sexual partners

  31. Gonococcal arthritis • Ceftriaxone 1gm IV or IM q24 hours • Spectinomycin 2 gm IV or IM q12 hours for ceph allergic patients • May use fluoroquinolones if susceptible

  32. Parvovirus B19 Arthritis • Small non-enveloped DNA virus • Erythrovirus genus • Replicates only in erythrocyte precursors • Transmission • Respiratory, parenteral, vertical • 25-68% of infections are asymptomatic

  33. Erythema Infectiosum • “5th disease” • 10% of children and 50% of adults have joint symptoms

  34. Parvovirus B19 Arthritis • Begins about 2 weeks after infection • Symmetrical involvement of the small joints of the hands and wrists and the knees • Usually resolves in about a month without joint damage • 20% may have persistent disease**

  35. Parvovirus B19 • Clinical features may mimic an early autoimmune disease • High prevalence of autoantibodies • RF, ANA, ACA, ANCA, anti-ds DNA • May persist for some time after infection is cleared • Has been implicated in the pathogenesis in both RA and SLE

  36. Diagnosis and Therapy • Parvovirus B19 IgM + • Parvovirus B19 IgG indicates past infection. • highly prevalent in the general population since asymptomatic infxn is very common. • PCR can be used • Immuncompromised people may not mount an antibody response • Therapy is supportive • NSAIDs • Steroids are rarely necessary

  37. Tuberculous arthritis • History of exposure is helpful • PPD may be negative • Synovial fluid stain usually negative • Culture may take 6-8 weeks to grow • Best yield is probably synovial biopsy

  38. PART 2

  39. POST ARTHROPLASTY INFECTIONS

  40. INCIDENCE • For knee generally low 0.1-2% • For hip 1-2%

  41. MECHANISM • Intraoperative seeding-low virulent • Blood spread • Fretting-micromotion between implants -DM -sepsis -steroid use -Long hospital stay -long theatre time>3hrs -blood loss > 1500cc -smoking

  42. Methods of prevention • Treatment of superficial and deep infection • I.V prophylactic antibiotics • Others-laminar flow -closed body exhaust suits -careful tissue handling -antibiotic cement -minimize theatre traffic

  43. BIOFILM • There are five stages of biofilm development 1Initial attachment-van der waals forces 2Irreversible attachment-cell adhesion structures, hydrophobicity,quorum sensing 3Maturation I: 4Maturation II: 5Dispersion:

  44. BIOFILM

  45. Biofilm • Pathophysiology has been greatly improved by the biofilm model • Conditions for biofilm formation: necrotic tissue and bone, which have a foreign-body effect and are colonized by bacteria. • Pathogens 1st form surface colonies, multiply.

  46. Biofilm • Matrix offers protection from mechanical influences and makes it harder for AB, body’s own defense cells, and Ig to penetrate, functioning as a diffusion barrier. • Pathogens pass from a high metabolic rate and rapid multiplication into greatly reduced metabolism and slowed biological Rx. • This can reduce their sensitivity to antibiotics by a factor of 10(3)

  47. Biofilm • Neutrophilic granulocytes penetrate the biofilm poorly and in the process lose their ability to phagocytose. • Apoptosis occurs with excessive complement activation and release of radicals and proteases, resulting in a local immune deficiency.

  48. Biofilm • In lower layers of the biofilm, conditions are anaerobic, reducing growth rate and metabolic activity of pathogens. • Insensitive to antibiotics. • After Tx has ended, return --->active mode, show resistance to the originally administered AB

  49. Biofilm • return from sessile to planktonic phase is possible, and clinically triggers local or systemic recurrence of Ix. • Biofilm population = permanent source of virulent pathogens • Safest Tx= surgical removal of sequestrum bearing biofilm

More Related